WealthTrust Asset Management’s Viking Therapeutics VKTX Stock Holding History

WealthTrust Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$251K	Buy	6,446 +212	+3%	+$6.85K	0.14%	83
2026 Q1	$203K	Buy	6,234 +72	+1%	+$2.31K	0.12%	91
2025 Q4	$217K	Buy	+6,162	New	+$218K	0.15%	71
2025 Q1	–	Sell	-6,923	Closed	-$279K	–	102
2024 Q4	$279K	Buy	6,923 +437	+7%	+$24.9K	0.2%	70
2024 Q3	$411K	Buy	6,486 +786	+14%	+$46.1K	0.31%	60
2024 Q2	$302K	Buy	5,700 +1,100	+24%	+$72.1K	0.22%	66
2024 Q1	$377K	Buy	+4,600	New	+$205K	0.29%	55

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

WealthTrust Asset Management's VKTX Position: Q2 2026 in Review

WealthTrust Asset Management increased its Viking Therapeutics (VKTX) stake by 3.4% in Q2 2026, buying an estimated $6.85K and bringing the position to 6,446 shares worth $251K. The position accounts for 0.14% of the portfolio, ranked #83.

WealthTrust Asset Management first reported a position in VKTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $411K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

WealthTrust Asset Management held 6,446 shares of Viking Therapeutics worth $251K as of Q2 2026.
WealthTrust Asset Management bought 212 Viking Therapeutics shares in Q2 2026, an estimated $6.85K.
Viking Therapeutics made up 0.14% of WealthTrust Asset Management's portfolio in Q2 2026, its #83 holding.
WealthTrust Asset Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 7 quarters since.
WealthTrust Asset Management's Viking Therapeutics position peaked at $411K in Q3 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on WealthTrust Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.